Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 36

1.

A retrospective evaluation of species-specific sensitivity for neurological signs in toxicological studies: Is the dog more sensitive than the non-human primate?

Backes K, Lorenz H, Laplanche L, Hudzik TJ, Potschka H, Hempel K.

Toxicol Lett. 2016 Jan 22;243:78-87. doi: 10.1016/j.toxlet.2015.12.007. Epub 2015 Dec 28.

PMID:
26732424
2.

The Utility of Impulsive Bias and Altered Decision Making as Predictors of Drug Efficacy and Target Selection: Rethinking Behavioral Screening for Antidepressant Drugs.

Marek GJ, Day M, Hudzik TJ.

J Pharmacol Exp Ther. 2016 Mar;356(3):534-48. doi: 10.1124/jpet.115.229922. Epub 2015 Dec 23.

PMID:
26699144
3.

Translational Biomarkers of Neurotoxicity: A Health and Environmental Sciences Institute Perspective on the Way Forward.

Roberts RA, Aschner M, Calligaro D, Guilarte TR, Hanig JP, Herr DW, Hudzik TJ, Jeromin A, Kallman MJ, Liachenko S, Lynch JJ 3rd, Miller DB, Moser VC, O'Callaghan JP, Slikker W Jr, Paule MG.

Toxicol Sci. 2015 Dec;148(2):332-40. doi: 10.1093/toxsci/kfv188.

4.

Effects of the δ opioid agonist AZD2327 upon operant behaviors and assessment of its potential for abuse.

Hudzik TJ, Pietras MR, Caccese R, Bui KH, Yocca F, Paronis CA, Swedberg MD.

Pharmacol Biochem Behav. 2014 Sep;124:48-57. doi: 10.1016/j.pbb.2014.05.009. Epub 2014 May 22.

PMID:
24857840
5.

Assessment of the abuse liability of ABT-288, a novel histamine H₃ receptor antagonist.

Hudzik TJ, Basso A, Boyce-Rustay JM, Bracken W, Browman KE, Drescher K, Esbenshade TA, Loberg LI, Lynch JJ 3rd, Brioni JD.

Psychopharmacology (Berl). 2013 Jul;228(2):187-97. doi: 10.1007/s00213-013-3027-7. Epub 2013 Feb 28.

PMID:
23455597
6.

Multiparameter exploration of piperazine derivatives as δ-opioid receptor agonists for CNS indications.

McCauley JP Jr, Dantzman CL, King MM, Ernst GE, Wang X, Brush K, Palmer WE, Frietze W, Andisik DW, Hoesch V, Doring K, Hulsizer J, Bui KH, Liu J, Hudzik TJ, Wesolowski SS.

Bioorg Med Chem Lett. 2012 Jan 15;22(2):1169-73. doi: 10.1016/j.bmcl.2011.11.088. Epub 2011 Dec 7.

PMID:
22197139
7.

4-Piperidin-4-ylidenemethyl-benzamides as δ-opioid receptor agonists for CNS indications: identifying clinical candidates.

Dantzman CL, King MM, Ernst GE, Wang X, McCauley JP Jr, Andisik DW, Brush K, Bui KH, Frietze W, Hoesch V, Liu J, Palmer WE, Spear N, Hudzik TJ, Wesolowski SS.

Bioorg Med Chem Lett. 2012 Jan 15;22(2):1174-8. doi: 10.1016/j.bmcl.2011.11.089. Epub 2011 Nov 30.

PMID:
22197137
8.

Preclinical pharmacology of AZD2327: a highly selective agonist of the δ-opioid receptor.

Hudzik TJ, Maciag C, Smith MA, Caccese R, Pietras MR, Bui KH, Coupal M, Adam L, Payza K, Griffin A, Smagin G, Song D, Swedberg MD, Brown W.

J Pharmacol Exp Ther. 2011 Jul;338(1):195-204. doi: 10.1124/jpet.111.179432. Epub 2011 Mar 28.

9.

Acute nicotine and phencyclidine increase locomotor activity of the guinea pig with attenuated potencies relative to their effects on rat or mouse.

Simmons MA, Werkheiser JL, Hudzik TJ.

Pharmacol Biochem Behav. 2010 Jan;94(3):410-5. doi: 10.1016/j.pbb.2009.10.002. Epub 2009 Oct 17.

PMID:
19840815
10.

Rat middle cerebral artery occlusion: correlations between histopathology, T2-weighted magnetic resonance imaging, and behavioral indices.

Peeling J, Corbett D, Del Bigio MR, Hudzik TJ, Campbell TM, Palmer GC.

J Stroke Cerebrovasc Dis. 2001 Jul-Aug;10(4):166-77.

PMID:
17903821
11.

Synthesis of novel quinolone and quinoline-2-carboxylic acid (4-morpholin-4-yl-phenyl)amides: a late-stage diversification approach to potent 5HT1B antagonists.

Horchler CL, McCauley JP Jr, Hall JE, Snyder DH, Craig Moore W, Hudzik TJ, Chapdelaine MJ.

Bioorg Med Chem. 2007 Jan 15;15(2):939-50. Epub 2006 Oct 20.

PMID:
17126021
12.

Behavioral pharmacology of AR-A000002, a novel, selective 5-hydroxytryptamine(1B) antagonist.

Hudzik TJ, Yanek M, Porrey T, Evenden J, Paronis C, Mastrangelo M, Ryan C, Ross S, Stenfors C.

J Pharmacol Exp Ther. 2003 Mar;304(3):1072-84.

13.

T2-weighted MRI correlates with long-term histopathology, neurology scores, and skilled motor behavior in a rat stroke model.

Palmer GC, Peeling J, Corbett D, Del Bigio MR, Hudzik TJ.

Ann N Y Acad Sci. 2001 Jun;939:283-96.

PMID:
11462782
14.
15.

Disruption of acquisition and performance of operant response-duration differentiation by unilateral nigrostriatal lesions.

Hudzik TJ, Howell A, Georger M, Cross AJ.

Behav Brain Res. 2000 Sep;114(1-2):65-77.

PMID:
10996048
16.

Antiparkinson potential of delta-opioid receptor agonists.

Hudzik TJ, Howell A, Payza K, Cross AJ.

Eur J Pharmacol. 2000 May 19;396(2-3):101-7.

PMID:
10822062
17.

Long-term functional end points following middle cerebral artery occlusion in the rat.

Hudzik TJ, Borrelli A, Bialobok P, Widzowski D, Sydserff S, Howell A, Gendron P, Corbett D, Miller J, Palmer GC.

Pharmacol Biochem Behav. 2000 Mar;65(3):553-62.

PMID:
10683498
18.

The low-affinity, use-dependent NMDA receptor antagonist AR-R 15896AR. An update of progress in stroke.

Palmer GC, Cregan EF, Bialobok P, Sydserff SG, Hudzik TJ, McCarthy DJ.

Ann N Y Acad Sci. 1999;890:406-20. Review.

PMID:
10668446
19.

Behavioral effects of AR-R 15849, a highly selective CCK-A agonist.

Simmons RD, Kaiser FC, Hudzik TJ.

Pharmacol Biochem Behav. 1999 Mar;62(3):549-57.

PMID:
10080250
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk